Search
for

    GlossaryPyrilutamide (KX-826)

    topical treatment blocking androgen receptors to combat hair loss

    Pyrilutamide, also known as KX-826, is a topical non-steroidal anti-androgen being developed for the treatment of androgenetic alopecia (pattern hair loss). It works by blocking androgen receptors in hair follicles, which can help reduce hair loss and potentially promote hair regrowth.

    🛒 Where to find KX-826

    Tracking 3 topical products by companies like Amazon. View all 3 products »

    Learn

    2 / 2 results

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

    Research

    5 / 176 results

    Community Join

    5 / 379 results

      community KX-826 , a small change in the pipeline

      in Research/Science  6 upvotes 6 days ago
      KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

      community KX-826 alone to stop hairloss???

      in Treatment  13 upvotes 3 months ago
      A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

      community KX-826 users: 0.5% vs 0.9% vs foam

      in Technology  6 upvotes 6 months ago
      KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

      community KX-826 1% Phase II Results from China Just Dropped

      in Research/Science  37 upvotes 6 months ago
      KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.